Shionogi & Co. stock slumped 16 percent in Tokyo after preclinical studies showed its experimental COVID-19 drug disturbed fetal development, triggering concerns about its approval.
Kyodo News reported that the drug likely wouldn’t be recommended for pregnant women without giving attribution.
